Jim Simons Metacrine, Inc. Transaction History

Renaissance Technologies LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.35 - $0.46 $1,715 - $2,254	-4,900 Reduced 0.85%	574,636 $257,000
Q3 2022 Nov 14, 2022	SELL	$0.43 - $0.55 $4,000 - $5,117	-9,304 Reduced 1.58%	579,536 $281,000
Q2 2022 Aug 12, 2022	BUY	$0.36 - $0.63 $59,666 - $104,416	165,740 Added 39.17%	588,840 $294,000
Q1 2022 May 13, 2022	BUY	$0.43 - $0.7 $83,334 - $135,660	193,800 Added 84.52%	423,100 $258,000
Q4 2021 Feb 11, 2022	SELL	$0.64 - $3.83 $34,432 - $206,054	-53,800 Reduced 19.0%	229,300 $155,000
Q3 2021 Nov 12, 2021	BUY	$2.61 - $3.84 $530,352 - $780,288	203,200 Added 254.32%	283,100 $971,000
Q2 2021 Aug 13, 2021	BUY	$3.37 - $5.73 $269,263 - $457,827	79,900 New	79,900 $304,000

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.